#South Korea #Seoul #Osteoarthritis #NEXTBIOMEDICAL #Nexsphere-F

Nexsphere-F™ Clinical Study Unveils Encouraging Findings for Knee Osteoarthritis

Introduction

In a groundbreaking development in the field of pain management for knee osteoarthritis, NEXTBIOMEDICAL CO., LTD., a leading medical device innovator from South Korea, has announced the publication of a clinical study regarding their product, Nexsphere-F™. Featured in the esteemed journal Radiology, which enjoys a notable impact factor of 17.6, the study reveals compelling evidence supporting the effectiveness of Nexsphere-F™ in alleviating pain associated with this prevalent degenerative condition.

Study Overview

The research titled "Genicular Artery Embolization Using Rapidly Resorbable Gelatin-based Microspheres for Osteoarthritis-related Knee Pain" was conducted by a team from Charité – Universitätsmedizin Berlin, recently ranked the eighth-best hospital globally by Newsweek. This study is regarded as the largest prospective observational assessment focused on genicular artery embolization (GAE) employing a resorbable embolic agent, highlighting its significance.

A total of 194 patients suffering from knee osteoarthritis—who had not achieved relief from traditional conservative treatments like corticosteroid and hyaluronic acid injections—were enrolled in this study. The aim was to assess the safety and clinical outcomes associated with GAE utilizing Nexsphere-F™. Importantly, this prospective study design is highly esteemed as it adheres to a well-structured protocol, thus offering a stronger clinical evidence base compared to retrospective analyses.

Results and Findings

Out of a total of 239 conducted procedures, the use of Nexsphere-F™ achieved an extraordinary technical success rate of 100%. Patients reported a notable decrease in pain levels, with scores measured on the Numeric Rating Scale dropping from a median of 7 prior to the procedure to just 3 after 12 months, equating to a 57% reduction in pain. Moreover, assessments conducted via the Knee Injury and Osteoarthritis Outcome Score (KOOS) indicated significant enhancements in knee function and life quality metrics across the board. Remarkably, around 80% of participants attained a minimum clinically important difference (MCID) in their outcomes, affirming the clinical effectiveness of the intervention. Encouragingly, no moderate or severe adverse events were reported as a result of the procedure.

Implications for Future Developments

The impressive results garnered from this clinical study position Nexsphere-F™ favorably for further expansion into the European medical market, where it is already on track, holding CE marking under the Medical Device Directive (CE-MDD). Additionally, the findings are anticipated to significantly bolster efforts to secure insurance reimbursement and elevate the adoption rate among healthcare institutions. Meanwhile, the ongoing RESORB clinical trial designed to support FDA approval in the USA is advancing without hitches.

The study's authors described Nexsphere-F™ as a transformative embolic agent, offering an advantageous safety profile compared to traditional permanent microspheres and imipenem-cilastatin (IPM-CS), which are known for higher incidences of skin discoloration—65% and 18% in previous studies respectively. In vigilance, Nexsphere-F™ demonstrated transient skin discoloration in merely 6.3% of procedures, subsiding within a swift 24 hours.

A spokesperson from NEXTBIOMEDICAL asserted that the publication of this study in Radiology reflects robust international recognition for the clinical value and distinctiveness of Nexsphere-F™. This development underlines the company's relentless pursuit to establish Nexsphere-F™ as a global standard in the domain of genicular artery embolization, thereby facilitating new pathways to effective pain management for knee osteoarthritis patients.

Conclusion

The promising outcomes of the Nexsphere-F™ clinical study herald a new chapter in the management of knee osteoarthritis pain. With continued research and validation, the expectation remains high that this innovative solution can transform patient experiences and treatment efficacy globally.